Automated Insulin Delivery (AID) System Integration

Introduction to Automated Insulin Delivery (AID) Systems

An automated insulin delivery (AID) system links three parts: a continuous glucose monitor (CGM), an insulin pump, and software (the algorithm) that changes how much insulin the pump gives based on the sensor's readings [6]. The FDA calls these "artificial pancreas device systems" and notes they also go by closed-loop or automated insulin delivery systems [2]. The first hybrid closed-loop system it approved was Medtronic's MiniMed 670G, on September 28, 2016 [2]. "Hybrid" means the person still does part of the work. With Tandem's Control-IQ, for example, users deliver their own meal boluses while the software handles the rest [6].

Innovation and Patents

Making an AID system means solving two problems at once: hardware that talks reliably over a wireless link, and an algorithm that decides on insulin every few minutes. Three companies show how differently that has played out. Medtronic's diabetes business now operates as MiniMed (Nasdaq: MMED) [4], Tandem Diabetes Care builds its algorithm into the t:slim X2 pump [8], and Abbott completed its acquisition of Bigfoot Biomedical on September 22, 2023 [9]. Patents related to AID systems, including predictive algorithms, user interfaces, and device integration, are held by these and other companies [1].

Manufacturers and Product Lines

• MiniMed (formerly Medtronic Diabetes): As of October 2026, its AID pumps are the MiniMed 780G and the MiniMed Flex, an app-controlled pump that launched in the US on June 17, 2026 [4][5]. Flex is FDA-cleared for type 1 diabetes from age 7 and for adults with insulin-requiring type 2 diabetes [4]. Both pumps pair with sensors from MiniMed's lineup: the Simplera Sync works with either, and the Guardian 4 with the 780G [5]. The MiniMed 670G and 770G are earlier systems; the FDA describes the 780G as similar to the 770G, with upgraded algorithms and added features [3].
• Tandem Diabetes Care: The t:slim X2 pump runs Control-IQ+ technology [8]. The FDA cleared Control-IQ+ in February 2025 for type 1 diabetes from age 2 and type 2 diabetes in adults, with an earlier Control-IQ version as its predicate device; the original Control-IQ was authorized in December 2019 [6][7]. Neither version only automates basal insulin. Both raise, lower or stop background (basal) insulin and can also give a correction bolus when glucose is predicted to go above a set threshold [6][7].
• Bigfoot Biomedical: The Bigfoot product the FDA cleared, the Bigfoot Unity Diabetes Management System (May 2021), isn't a pump system. It pairs an Abbott CGM sensor with caps for insulin pens that display dose information [10]. Abbott now owns the company [9]. We found no FDA record for a Bigfoot pump-based AID system, so the status of that work is unclear.

Product Comparison

The biggest practical difference between the two pump makers is sensor choice. Tandem says several CGMs work with the t:slim X2, including the Dexcom G7 and the FreeStyle Libre 3 Plus [8]. MiniMed's sensor comparison page lists only sensors sold under the MiniMed name for its pumps, including the Instinct sensor [5].

Automatic correction boluses are now on both sides, but they arrived at different times. Control-IQ could deliver them when the FDA authorized it in 2019 [6]. At Medtronic, the auto correction bolus first came with the MiniMed 780G, approved in April 2023; the FDA lists it as a feature the 770G didn't have [3]. MiniMed says the Flex runs its SmartGuard algorithm, which adjusts and corrects delivery as often as every 5 minutes [4].

The pivotal trials point the same way, though they were built differently. In Control-IQ's six-month randomized pivotal trial, 168 people with type 1 diabetes aged 14 to 71 took part. Time in the target glucose range rose from 61% to 71% with the closed-loop system and stayed at 59% with a standard sensor-augmented pump [11]. The 780G trial had no control group: across 157 adolescents and adults, time in range went from 68.8% during a run-in period to 74.5% once automatic basal and correction dosing were switched on [12]. Because the designs differ, those numbers shouldn't be compared head to head. Studies of what it's like to use these systems report reassurance, less anxiety and better sleep [13].

Pitfalls, Warnings, and Issues

The FDA's review of Control-IQ spells out the risks plainly. Low blood glucose (including severe hypoglycemia), high blood glucose and diabetic ketoacidosis (DKA) can follow software faults, bad CGM data, lost connections between devices, gaps in training, or infusion sets that keep failing [6]. Two software problems surfaced during the Control-IQ pivotal study, and each paused the study until a patch fixed it [6]. The human side matters too. A review of user experience found the benefits counterbalanced by variable trust in the system, technical glitches and trouble fitting it into everyday life [13]. How to set up or adjust any of these systems is a decision for your care team.

Conclusion

As of October 2026, the current algorithms from both major pump makers adjust basal insulin automatically and can give correction doses without being asked: SmartGuard on the MiniMed 780G and Flex, and Control-IQ+ on the t:slim X2 [3][4][7][8]. What still separates them is which sensors each pump accepts and how the hardware fits a person's day.